Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 7:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1561–1584 of 2,756 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: High Activity Clear all

Conditions: Pre Diabetes, Type2 Diabetes
Interventions: AI-Powered Diabetes Prevention Chatbot; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Chronic Intractable Pain
Interventions: Intraspinal Gabapentin; Drug
Lead sponsor: MedtronicNeuro; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 14
States / cities: Little Rock, Arkansas • Napa, California • Sarasota, Florida + 11 more

Conditions: Cystic Fibrosis
Interventions: Aerobic exercise, Resistance exercise, Flexibility and postural exercise, Balance exercise; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 6 Years to 21 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Brain Care Score, Exercise, Hypertension, BMI
Interventions: Exercise Intervention to improve overall Brain Health; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 35 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Cocaine Use Disorder, Tobacco Use Disorder
Interventions: metyrapone & oxazepam, Placebo; Drug
Lead sponsor: Embera NeuroTherapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Long Beach, California • Baton Rouge, Louisiana

Conditions: Aphasia, Stroke
Interventions: Adaptive Spacing Condition, High-Item Non-Adaptive Spacing Condition, Low-Item Non-Adaptive Spacing Condition; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Type 1 Diabetes
Interventions: High Dose SAB-142, Low Dose SAB-142, Placebo; Drug · Other
Lead sponsor: SAb Biotherapeutics, Inc.; Industry
Eligibility: 5 Years to 40 Years
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 22
States / cities: San Francisco, California • San Jose, California • Aurora, Colorado + 19 more

Conditions: Acute Leukemia, Chronic Myelogenous Leukemia, Myelodysplasia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Lymphoma, B-Cell, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Hodgkin's Lymphoma
Interventions: Tacrolimus (ARM with Methotrexate), Tacrolimus (ARM with MMF and Cyclophosphamide), Methotrexate (ARM with Maraviroc), Methotrexate (ARM with Bortezomib), Maraviroc, Bortezomib, Mycophenolate mofetil, Cyclophosphamide; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 279 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 30
States / cities: Duarte, California • Stanford, California • Gainesville, Florida + 24 more

Conditions: Lymphoproliferative Disorder, Multiple Myeloma
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Electronic Health Record Review, Follow-Up, Genetic Counseling, Genetic Testing; Procedure · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 7
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Albert Lea, Minnesota + 4 more

Conditions: Cancer, Fatigue
Interventions: Physical Activity/Physical Functioning, Quality of Life; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Circadian Dysregulation, Light Exposure, Pediatric Critical Illness
Interventions: Light Therapy; Other
Lead sponsor: Laura Beth Kalvas; Other
Eligibility: 4 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Osteoarthritis of the Knee
Interventions: ABT-652, Placebo, Naproxen; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 40 Years to 75 Years
Enrollment: 322 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 23
States / cities: Chandler, Arizona • Tempe, Arizona • Tucson, Arizona + 20 more

Conditions: Trauma Injury, Child, Only, Posttraumatic Stress Disorder, Parents
Interventions: Caregivers' Aid to Accelerate Recovery after pediatric Emergencies (CAARE); Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: Not listed
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Respiratory Syncytial Viruses
Interventions: Lumicitabine, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 28 Days to 36 Months
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 6
States / cities: Long Beach, California • Kansas City, Missouri • Syracuse, New York + 3 more

Conditions: Lung Diseases, Asthma
Interventions: Counseling, Urine Cotinine Feedback, Contingent Incentives, Usual education program; Behavioral
Lead sponsor: San Diego State University; Other
Eligibility: 8 Years to 13 Years
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: San Diego, California

Conditions: Pediatric Obesity, Insulin Resistance
Interventions: High-fat Challenge; Dietary Supplement
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 8 Years to 17 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Hepatitis C, HIV Infections
Interventions: Efavirenz, Emtricitabine/Tenofovir disoproxil fumarate; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 2
States / cities: Cincinnati, Ohio • Richmond, Virginia

Conditions: Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Interventions: Androgen Deprivation Therapy (ADT), Androgen Receptor Pathway Inhibitor (ARPI), Prostate Radiation, Docetaxel; Drug · Radiation
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Virtual Reality, Augmented Reality, IV Stick, Mask Induction, Ambulatory Surgery, Pain, Anxiety
Interventions: Oculus Go VR, Mira Prism VR; Device
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 10 Years to 21 Years
Enrollment: 450 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Bipolar Disorder
Interventions: cognitive-behavior therapy (CBT); Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 24 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Proliferative Diabetic Retinopathy (PDR)
Interventions: Aflibercept 8mg; Drug
Lead sponsor: Edward Wood, MD; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Austin, Texas • Bellaire, Texas • San Antonio, Texas

Conditions: Impaired Hepatic Function
Interventions: eravacycline; Drug
Lead sponsor: Tetraphase Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 3
States / cities: Lakewood, Colorado • Orlando, Florida • Knoxville, Tennessee

Conditions: Heart Disease, Cardiovascular Health Status
Interventions: Nutrition Education, PRO-CVH, Healthy Conversation Skills, Medically tailored groceries/cooking classes; Behavioral
Lead sponsor: Amrik Singh Khalsa; Other
Eligibility: 6 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: HIV Infections
Interventions: Couples HIV testing and counseling, Individual HIV testing and counseling; Behavioral
Lead sponsor: Hunter College of City University of New York; Other
Eligibility: 17 Years to 65 Years · Male only
Enrollment: 384 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: Ann Arbor, Michigan • New York, New York

Search by objective public record fields.

Diabetes Prevention AI: Enhancing Prevention Strategies Using Personalized Nutrition and Fitness Coaching for the Next Generation

A Safety and Effectiveness Study of Intraspinal Gabapentin (MDT2004) for the Treatment of Chronic Pain

Comprehensive Exercise Training Program During Hospitalization for an Acute CF Exacerbation

An Exercise Intervention to Improve Overall Brain Health

Single and Multiple Rising Dose Study of Safety and PK of Metyrapone/Oxazepam Combination (EMB-001)

Adaptive Trial Scheduling in Naming Treatment for Aphasia

SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes

Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)

Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)

Active Living After Cancer: Implementation Within Be Well Acres Homes

Feasibility of Light Therapy in the Pediatric Intensive Care Unit (ICU)

A Study of ABT-652 in Adults With Osteoarthritis Pain of the Knee

Using mHealth to Improve Emotional Recovery After Pediatric Injury

A Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) Regimens in Hospitalized Infants and Children Aged 28 Days to 36 Months Infected With Respiratory Syncytial Virus

Environmental Tobacco Smoke Exposure Reduction in High-Risk Preteens

High-fat Meal Challenge in Pediatrics

Effects of Anti-HIV Drugs on the Hepatitis C Virus (HCV) in Adults Infected With Both HCV and HIV

RISK-ADAPT Protocol in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Virtual Reality to Reduce Pre-Operative Anxiety

Cognitive-Behavior Therapy for Young Adults With Bipolar Disorder

High Dose Eylea for Proliferative Diabetic Retinopathy Outcomes

A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With Impaired Hepatic Function and Healthy Subjects

Pathways to Prevention Food-is-Medicine Trial

Evaluating the Efficacy of Annual CHTC Retesting Among Male Couples at High Risk of HIV Infection